Preventing nephropathy in patients with type 2 diabetes.
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001713:Biphenyl Compounds / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000150:complications / Q000517:prevention & control*; D019468:Disease Management; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D000077405:Irbesartan; D007676:Kidney Failure, Chronic / Q000150:complications / Q000517:prevention & control; D019808:Losartan / Q000008:administration & dosage; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy; D013777:Tetrazoles / Q000008:administration & dosage; D016896:Treatment Outcome; D014481:United States
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan; D019808:Losartan